Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
D000328:Adult; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000096:biosynthesis; D015214:Antigens, Differentiation, Myelomonocytic / Q000096:biosynthesis; D001663:Bilirubin / Q000097:blood; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D015331:Cohort Studies; D004347:Drug Interactions; D005260:Female; D000079982:Gemtuzumab; D006504:Hepatic Veno-Occlusive Disease / Q000150:complications / Q000209:etiology*; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications; D063268:Sialic Acid Binding Ig-like Lectin 3; D033581:Stem Cell Transplantation / Q000009:adverse effects; D013997:Time Factors; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D002756:Cholagogues and Choleretics; D000922:Immunotoxins; D063268:Sialic Acid Binding Ig-like Lectin 3; D014580:Ursodeoxycholic Acid; D000079982:Gemtuzumab; D001663:Bilirubin